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INTRODUCTION
Mesenchymal tumours of the gastrointestinal tract
are classified into four main categories based on light
a n d e l e c t r o n m i c r o s c o p y a s w e l l a s
immunohistochemistry. These include those that
show smooth muscle differentiation (leiomyoma,
leiomyoblastoma, leiomyosarcoma), those that show
neural/schwannian differentiation (schwannoma,
malignant peripheral nerve tumours [MPNST]),
those that appear to differentiate in both directions,
and those that show no (null) differentiation at all .
Recently, a molecular genetic abnormality resulting
in over expression of the tyrosine kinase growth
receptor, c-kit has been recognised as vital in the
pathogenesis of a significant proportion of these
tumours. These have been linked histogenetically to
the interstitial cells of Cajal which express c-kit.
The importance of detecting this mutation has been
greatly emphasized by the finding that a drug
STI571, (imatinib [Glivec , Gleevec ]; Novartis,
Basel, Switzerland) which acts to inhibit the c-kit
receptor, has a dramatic clinical therapeutic effect on
inoperable and metastatic cases of this class of
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This drug which also selectively inhibits other
tyrosine kinases like BCR-ABL [chronic myeloid
leukaemia] ABL and PDGFR, is more effective and
has less severe side effects than standard
chemotherapeutic regimen because of the different
mechanism of action (specific growth receptor
molecule inhibition, rather than general cytotoxicity)
. STI571 has therefore heralded a new era of
molecular biology based anti-tumour therapy that
promises to be revolutionary.
These events led to the consensus conference
reclassification of stromal/mesenchymal tumours of
the gastrointestinal tract. The new classification
sepa ra te s in to a d is t i nc t g roup , those
stromal/mesenchymal tumours of the gastrointestinal
tract in which a c-kit mutation is detected by
immunohistochemical reaction with the CD117
antibody, and these are referred to as
. The diagnostic label
implies expectation of a response to therapy
with STI571 and is hinged on immunohistochemical
de mons t r a t i o n of C D 117 p os i t i v i t y in
stromal/mesenchymal tumours of the gastrointestinal
tract .
These recent advances have been made based on
studies of patients and materials derived from the
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ABSTRACT
Key Words:
Mesenchymal tumours of the gastrointestinal tract (GIT) are uncommon. Recent progress in the understanding
of the biology and origin of these tumours has led to their reclassification. A new subclass designated
Gastrointestinal Stromal Tumours (GIST) is diagnosed based on the presence of a mutational over expression
of c-kit protein that is thought to be critical in the pathogenesis of these tumours. This new class of tumours may
form the majority of gastrointestinal mesenchymal tumours. Even though the diagnosis of GIST is mainly
based on positive staining with CD117, a minority of tumours with histological characteristics of GIST are
CD117 negative and are classified as CD117 negative GIST.
In this first review of mesenchymal GIT tumours from Nigeria, we present 11 cases of mesenchymal tumours
of the gastrointestinal tract seen within a six-year period at our centre. Immunohistochemistry was performed
on 7 of them in which histological appearances suggested GIST. Only two cases had all the criteria defined in
the consensus conference on the diagnosis of GIST. Our findings, albeit in a very small sample, contrasts with
what obtains in developed countries in the proportion of GIT mesenchymal tumours that are truly GIST. This
raises a question to be answered on the true nature and proportion of gastrointestinal strumal tumours among
GIT tumours in Nigerian patients.
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fibrosarcoma and nine possible gastrointestinal
stromal tumors. The tissue block of two of the
possible cases of GIST could not be traced.
Immunohistochemistry was done on the remaining
seven cases. There were three males and four
females with age range of 26 year to 62 years (mean
age 43.4 years). Six of the tumours were gastric in
origin while one was from the jejunum. The gastric
tumours presented with massive upper
gastrointestinal haemorrhage in four patients, two of
whom had associated abdominal masses, the other
two patients presented with abdominal masses only.
The jejunal tumour presented with massive lower GI
haemorrhage. The duration of symptoms ranged
from 6 days to 1 year. Combinations of barium meal
and or abdominal ultrasound scan were used to make
a preoperative diagnosis of a gastric mass and or
ulcer in all the patients (Table 2). All the patients at
surgery had exophytic fleshy growths which were
still localized to the stomach in three cases. One
gastric and the jejunal tumour had infiltrated the
surrounding structures while two gastric tumours
had distant abdominal metastasis. All the gastric
tumours had partial gastrectomy except the two
patients with metastatic disease who had wide
excision of the primary gastric lesion. Small gut
resection with partial cystectomy was done for the
jejunal tumour. There was no procedure related
mortality.
On immunohistochemistry, tumour cells from two
patients (FAand NR) expressed CD34 in a strong and
diffuse manner, but CD117 (c-Kit) in a weak and
patchy manner. These cases are therefore considered
true c-kit positive GIST. Of the five patients whose
tumour cells were negative for CD117, two (UP and
UT) stained positively for smooth muscle marker,
SMA and negatively for NSE and synaptophysin.
These two were therefore considered frankly
leiomyosarcomas. Among the remaining three
patients, two (UL and UK) had tumours that stained
positively for NSE but were negative for all other
antibodies except CD34 while one was negative for
all markers except CD34. These three cases were
therefore considered c-kit negative GIST.
Immunohistochemistry (Table 3, Figures1, 2 and
3)
America, Europe and Asia, with little if any
contribution from African nations. Considering that
molecular genetic alterations in a given tumour may
and do differ between ethnic populations, and that
drug response and toxicity profile may be affected by
the gene's environment and behaviour, we thought it
should be important that stromal/mesenchymal
tumours of the gastrointestinal tract be similarly
studied in African populations. In this
communication, we present the first documented
immunohistochemical study of mesenchymal
tumours of the gastrointestinal tract in patients from
Nigeria.
We reviewed the histology of all tumors of the
gastrointestinal tract that were submitted to the
Pathology Department of the University of Nigeria
Teaching Hospital Enugu, Nigeria from January
2002 to December 2007. All cases of gastrointestinal
mesenchymal tumours diagnosed as possible GIST
on routine haematoxylin/eosin examination were
further subjected to immunohistochemistry. The
immunohistochemistry was performed at Harold
Wood Hospital UK and read by one of the authors
(IUO). It was performed manually using the standard
streptavidin-biotin-peroxidase technique and
followed the manufacturer's instructions for the
antibodies listed in table 1. The antibodies tested
included neuron specific enolase (NSE), smooth
muscle actin (SMA), desmin, synaptophysin, S100,
CD34 and CD117. Antigen retrieval for CD117 was
by heating the sections in 0.01M EDTA at pH 8.0 in
the microwave oven on high power for 17 minutes,
allowing boiling for 5 minutes. For all the other
antibodies, sections were heated in 0.01M citrate
buffer at pH 6.0 in the microwave oven on high
power for a total of 25 minutes, allowing boiling for
10 minutes. The slides were counterstained with
Gills hematoxylin.
Ninety six gastrointestinal tumors were received
during the period; eleven of them (11.4%) were
diagnosed as mesenchymal stromal tumours after
routine hematoxylin-eosin processing. Among these
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Table 1: Antibodies used in Immunohistochemistry of the Tumours.
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Antibody Manufacturer Clone Dilution
NSE ( neuron specific enolase) DAKO M0874 1/500
SMA (smooth muscle actin) Dakocytomation 1A4 1/25
Synaptophysin Dakocytomation SY38 1/5
CD34 Novocastra QBEND/10 1/20
CD117 Dakocytomation Rabbit Polyclonal 1/400
Patient's
initials


































NSE +ve -ve +ve -ve Not done Not done- very weak &
focal
SMA -ve -ve -ve +ve +ve -ve -ve
Synaptop
hysin
+ve -ve -ve -ve -ve Not done -ve
S100 Not done Not done Not done Not done Not done -ve -ve
CD34 +ve +ve +ve -ve +ve +ve +ve


























Diagnostic tool Op findings Procedure done
FA Barium meal: mass at lesser
curvature with ulcer crater
Gastric exophytic tumour with
mucosal protrusion and ulceration
Partia l gastrectomy,
Bilroth I
IC Barium meal: feeling defect in
stomach
10x14cm lesser curve gastric
tumour with 2 deeply ulcerated
areas
4/5 distal gastrectomy ,
Bil I
UL Ultrasound: gastric mass, Barium
meal: no mass or ulcers in stomach,
OGD: inflammation and heamatoma
in antrum
20 x20cm gastric corpus tumor,





UP Barium enema: normal, Ultrasound:
echogenic mass 10x12cm related to
the posterior wall of urinary bladder
Fleshy exophytic jejunal mass,
adherent to urinary bladder,
Small intestina l
resection with partial
excision of blader wall
UT Ultrasound: retroperi toneal cystic
mass possibly pancreatic pseudo
cyst
huge cystic mass with a solid
mushroom like componenent
originating from gastric fundus
and cardia.
wide excision
NR Ultrasound: gastric mass; Barium
meal: filling defect in cardia and
lesser curvature of stomach
18 x26cm mass in cardia, fundus
and body of stomach
proximal gastrectomy
UK Ultrasound scan = malignant mass
in retrogastric space with liver
metastasis.
10 cm gastric tumour in the
retrogastric area, adherent to tail







Table 2: Diagnostic and Operative Findings.
Table 3: Pathology
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DISCUSSION
Most mesenchymal tumours of the gastrointestinal
tract are said to be either GIST or of smooth muscle
type . In eleven gastrointestinal mesenchymal
tumours seen in our centre, two were true CD 117
positive GIST while two cases were histologically
and immunohistochemically diagnosed as smooth
muscle tumours. Three other patients were
unclassified and are considered C-kit negative GIST.
Schwanoma, a rare spindle cell tumour of the
stomach may grow to a large size and therefore is a
differential here. However apart from the absence of
any distinct histologic features to suggest this
diagnosis, gastric schwannomas rarely ulcerate the
mucosa and are infrequently positive with CD34 as
seen in these three cases. The other rare possibility of
fibromatosis is also excluded not only by the gross
appearance of the tumours but also by the negative
reaction for SMA and positive reaction for CD34 in
the three unclassified cases (IC, UL and UK). In the
absence of reliable immunohistochemical/histologic
features of smooth muscle or neural differentiation in
the three cases (IC, UL and UK), it seems reasonable
to classify them as probable GISTs especially with
their positivity with Cd34.
O n l y t w o o f o u r c a s e s f u l f i l l e d t h e
immunohistochemical diagnostic criteria set out in
the consensus approach reached at the US National
Institutes of Health GIST workshop of April 2001 .
According to that consensus, a rare GIST may be
CD117 negative in the following circumstances.
1. An immunohistochemically inert sample
possibly as a result of fixation or other
processing artefact. The strong reaction with
CD34 in our cases and other positive internal
control parameters suggests that this does not
apply.
2. Sampling error such as may be seen in needle
biopsies, would also not apply in our cases.
3. Cessation of KIT expression due to some of
clonal evolution perhaps following STI571
therapy. None of our patients has received the
drug.
4. A small percentage (<2%) that lack either KIT
mutations and/or KIT over expression.
It would appear that three of our cases belong to this
last category of true CD117-negative GIST. This of
course raises the question of the true proportion of
CD117-negative GIST and whether this varies with
the environment in which the study was done. Our
numbers are too small for a generalization to be made
but it raises a question whether the proportion of
CD117-negative GIST from our population might be
higher than the 2% recognized in the consensus
document. Indeed some authors have questioned the
position that makes CD117 positivity an absolute






Case FA; immunohistochemistry with
CD34 showing strong positive staining with
tumour. Note muscularis mucosa is negative.
Magnification x10.
Case FA; immunohistochemistry with
CD117 (c-kit) showing positive staining of
tumour. Magnification x4.
Case UL: Immunohistochemistry with
CD117 (c-kit) showing negative tumour reaction
(note positive internal control with mucosal mast
cells).
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considering that this does not necessarily indicate
that a mutation of the gene is present . Conversely a
KIT mutation may exist in the absence of the
immunohistochemically detectable marker.
In summary we have analysed eleven cases of
gastrointestinal mesenchymal tumours seen in our
hospital over a six year period.
Immunohistochemistry was performed in seven of
nine cases in which histology suggested GIST. Only
two cases had all the criteria defined in the consensus
conference on the diagnosis of GIST. Our findings
raise some questions on the true nature and
proportion of GIT mesenchymal tumours in our
environment that are GIST. A determination of this is
very crucial in knowing the usefulness of the new
targeted treatments for gastrointestinal strumal
tumours in our environment. Since this category of
GIT tumours is uncommon, more collaborative
studies between institutions from different parts of
Nigeria and Africa are needed in order to
meaningfully contribute to this area of tumour
pathology that promises to significantly change the
way this group of malignancies are managed.
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